Published in J Clin Oncol on April 15, 2002
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
Melanoma: a model for testing new agents in combination therapies. J Transl Med (2010) 1.39
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol (2005) 1.37
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res (2006) 1.32
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (2010) 1.19
Pink-eyed dilution protein modulates arsenic sensitivity and intracellular glutathione metabolism. Mol Biol Cell (2002) 1.14
Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs (2005) 1.13
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc (2014) 1.06
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer (2009) 1.05
Lung cancer immunotherapy. Clin Med Res (2005) 1.04
Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01
Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide (2008) 1.00
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer (2011) 0.98
Biochemotherapy for advanced melanoma: maybe it is real. J Clin Oncol (2002) 0.96
Immunotherapy of distant metastatic disease. Ann Oncol (2009) 0.96
Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline. Curr Oncol (2008) 0.93
Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res (2011) 0.92
The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am (2009) 0.92
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol (2015) 0.89
Translatability scoring in drug development: eight case studies. J Transl Med (2012) 0.89
Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol (2009) 0.89
Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Invest New Drugs (2005) 0.89
Surgery and sentinel lymph node biopsy. Semin Oncol (2007) 0.85
IPM chemotherapy in cytokine refractory renal cell cancer. Br J Cancer (2003) 0.84
Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist (2012) 0.83
Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. Contemp Oncol (Pozn) (2013) 0.82
Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol (2011) 0.82
Socioeconomic status and chemotherapy use for melanoma in older people. Can J Aging (2011) 0.80
Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci U S A (2004) 0.80
Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer (2012) 0.80
Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.80
Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract (2011) 0.79
Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol (2013) 0.79
Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. Mol Diagn Ther (2014) 0.78
Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology. J Cancer Res Clin Oncol (2013) 0.77
Identifying novel molecular structures for advanced melanoma by ligand-based virtual screening. J Chem Inf Model (2009) 0.77
Non-viral immune electrogene therapy induces potent antitumour responses and has a curative effect in murine colon adenocarcinoma and melanoma cancer models. Gene Ther (2014) 0.77
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. J Transl Med (2003) 0.77
Role of IL-2 in cancer immunotherapy. Oncoimmunology (2016) 0.76
Melanoma immunotherapy dominates the field. Ann Transl Med (2016) 0.75
The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma. J Adv Pract Oncol (2015) 0.75
BAP31, a promising target for the immunotherapy of malignant melanomas. J Exp Clin Cancer Res (2015) 0.75
Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses. Clin Med Insights Case Rep (2017) 0.75
A word of caution: do not wake sleeping dogs; micrometastases of melanoma suddenly grew after progesterone treatment. BMC Cancer (2013) 0.75
The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy. Lasers Med Sci (2017) 0.75
Accumulation of prohibitin is a common cellular response to different stressing stimuli and protects melanoma cells from ER stress and chemotherapy-induced cell death. Oncotarget (2017) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys (2002) 6.82
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol (2007) 3.79
Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol (2004) 3.38
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) (2012) 3.03
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials (2009) 2.79
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol (2007) 2.72
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials (2008) 2.71
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res (2002) 2.66
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer (2003) 2.64
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol (2008) 2.39
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Optimizing treatment of desmoid tumors. J Clin Oncol (2007) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol (2002) 2.13
A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet (2011) 2.05
Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer (2006) 2.04
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
Angiosarcoma of the breast. Cancer (2005) 1.98
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.82
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (2007) 1.79
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer (2002) 1.67
Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila) (2009) 1.66
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol (2002) 1.65
Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med (2010) 1.62
Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer (2009) 1.61
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol (2007) 1.61
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res (2009) 1.60
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst (2010) 1.59
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) (2009) 1.59
Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst (2007) 1.58
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys (2003) 1.57
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol (2010) 1.56
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res (2012) 1.55
Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics (2006) 1.54
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol (2005) 1.54
Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer (2010) 1.53
Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg (2006) 1.50
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer (2011) 1.50
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.50
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol (2002) 1.50
Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer (2004) 1.47
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg (2003) 1.45
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer (2006) 1.45
Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer (2009) 1.43
Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol (2004) 1.41
Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer (2002) 1.39
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control (2003) 1.39
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol (2009) 1.38
Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer (2006) 1.36
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother (2009) 1.36
Soft tissue sarcoma. J Natl Compr Canc Netw (2010) 1.34
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res (2011) 1.33
Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia. Cancer Prev Res (Phila) (2012) 1.33
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer (2012) 1.32
Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog (2010) 1.32
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila) (2008) 1.32
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res (2012) 1.32